Daniell Richard 4

What Happened

Daniell Richard, EVP, Europe Commercial at Teva Pharmaceutical Industries (TEVA), had 17,295 restricted share units vest on March 5, 2026 and those shares were converted/settled and sold the same day. The shares were sold in open-market transactions at a weighted average price of $31.67, generating proceeds of approximately $547,705. The filing shows the derivative settlement/conversion (code M) and the subsequent sale (code S); some shares were used to cover tax withholding tied to the vesting.

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 9, 2026 (timely).
• Sale: 17,295 shares sold, weighted-average price $31.67; price range reported $31.26–$32.34.
• Proceeds: ~$547,705 reported for the open-market sale.
• Derivative activity: 17,295 shares resulted from conversion/settlement of RSUs (code M); a related line shows $0 value consistent with RSU settlement/tax withholding.
• Plan/notes: Sales effected under a Rule 10b5-1 trading plan adopted Nov 10, 2025 (F3). Footnotes state all vested RSU shares were sold, including shares withheld for taxes (F4). RSU grant and vesting schedule originally granted Mar 5, 2025 (F6).
• ADS note: Ordinary shares may be represented by American Depositary Shares (1 ADS = 1 ordinary share) (F1).
• Shares owned after the transaction: not specified in the Form 4.

Context

• This was a routine vesting and immediate sale of restricted share units (cashless settlement/sale to cover taxes), not a market purchase. The disposition was executed under a pre-arranged 10b5-1 plan, which typically indicates the trades were scheduled in advance. Such sales are common following RSU vesting and do not by themselves indicate insider sentiment about the company.